Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.
Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F, Klamroth R, Knoebl P, Laffan M, Mahlangu J, Miesbach W, Dalsgaard Nielsen J, Martín-Salces M, Angchaisuksiri P. Chowdary P, et al. Among authors: laffan m. J Thromb Haemost. 2015 May;13(5):743-54. doi: 10.1111/jth.12864. Epub 2015 Apr 6. J Thromb Haemost. 2015. PMID: 25641556 Free article. Clinical Trial.
Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.
Mannucci PM, Kempton C, Millar C, Romond E, Shapiro A, Birschmann I, Ragni MV, Gill JC, Yee TT, Klamroth R, Wong WY, Chapman M, Engl W, Turecek PL, Suiter TM, Ewenstein BM; rVWF Ad Hoc Study Group. Mannucci PM, et al. Blood. 2013 Aug 1;122(5):648-57. doi: 10.1182/blood-2013-01-479527. Epub 2013 Jun 18. Blood. 2013. PMID: 23777763 Free PMC article. Clinical Trial.
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, Symington E, Quon DV, Wang JD, Peerlinck K, Pipe SW, Madan B, Key NS, Pierce GF, O'Mahony B, Kaczmarek R, Henshaw J, Lawal A, Jayaram K, Huang M, Yang X, Wong WY, Kim B; GENEr8-1 Trial Group. Ozelo MC, et al. Among authors: laffan m. N Engl J Med. 2022 Mar 17;386(11):1013-1025. doi: 10.1056/NEJMoa2113708. N Engl J Med. 2022. PMID: 35294811 Clinical Trial.
von Willebrand's disease: a report from a meeting in the Åland islands.
Berntorp E, Peake I, Budde U, Laffan M, Montgomery R, Windyga J, Goodeve A, Petrini P, von Depka M, Miesbach W, Lillicrap D, Federici AB, Lassila R, White G. Berntorp E, et al. Among authors: laffan m. Haemophilia. 2012 Sep;18 Suppl 6(0 6):1-13. doi: 10.1111/j.1365-2516.2012.02925.x. Haemophilia. 2012. PMID: 22906074 Free PMC article.
Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort.
Collins PW, Mathias M, Hanley J, Keeling D, Keenan R, Laffan M, Perry D, Liesner R; UK Haemophilia Centre Doctors' Organisation. Collins PW, et al. Among authors: laffan m. J Thromb Haemost. 2009 May;7(5):787-94. doi: 10.1111/j.1538-7836.2009.03332.x. Epub 2009 Mar 5. J Thromb Haemost. 2009. PMID: 19320828 Free article.
287 results